PARP1 and myeloid leukemia: ASC enhances the cytotoxic effect of a PARP1/2 inhibitor, olaparib, on humanacute myeloid leukemia (AML) cells [52].Probably, this is a case of synthetic lethality: TET-mediated DNA oxidationcaused by ASC sensitizes AML cells to PARP inhibition due to the impossibilityof removing non-canonical bases from DNA.